Zymeworks Inc. Common Stock (ZYME) is a Healthcare · Biotechnology company listed on NASDAQ. Price $26.60 (-3.20%), Market cap $1.83B, 52-week low–high $11.22 ~ $28.56.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuv
Financial statements, price targets, institutional (13F) holdings and related news for Zymeworks Inc. Common Stock are updated in real time on BlackAll Trade.
Zymeworks Inc. Common Stock trades at $26.60 (-3.20%). Real-time quotes and charts are available on BlackAll Trade.
Zymeworks Inc. Common Stock has a market cap of about $1.83B.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody p